About This Topic

The Octreotide Dose Calculator for Sulfonylurea Hypoglycemia provides dosing recommendations for managing hypoglycemia caused by sulfonylurea medications. Octreotide, a somatostatin analog, works by inhibiting the release of insulin from the pancreas, directly counteracting the effect of sulfonylurea overdose and preventing recurrent hypoglycemia.

This information is for licensed healthcare professionals. Clinical judgment should always be used alongside any tool’s output.

Outputs Explained

The calculator provides patient-specific dosing regimens based on population (adult or pediatric) and weight:

• Initial Bolus Dose: The first dose administered to rapidly control insulin secretion. For pediatric patients, this is a weight-based calculation with a maximum cap.
• Intermittent Dosing: A schedule of follow-up doses given every 6-12 hours to maintain control if a continuous infusion is not used.
• Continuous Infusion: An alternative to intermittent dosing, providing a steady rate of octreotide administration, typically used for severe or refractory cases.

How to Use the Calculator

To determine the appropriate octreotide dose, follow these steps:

1. Select Patient Population: Choose either ‘Adult’ or ‘Pediatric’.
2. Enter Patient Weight: Input the patient’s weight and select the correct unit (kg or lbs).
3. Enter Patient Age (for Pediatrics): If ‘Pediatric’ is selected, provide the patient’s age in years or months. This helps provide clinical context, though dosing is weight-based.
4. Calculate: The tool will display the recommended initial and maintenance dosing options.

Dosing Overview

Octreotide is an essential adjunct to dextrose administration for managing sulfonylurea-induced hypoglycemia.

• Adults: The standard initial bolus is 100 mcg (IV or SC). Maintenance can be either 50-100 mcg every 6-12 hours or a continuous IV infusion of 50-125 mcg/hour.
• Pediatrics: Dosing is weight-based. The typical regimen is 1.5 mcg/kg (up to a maximum of 50 mcg per dose) for the initial bolus and subsequent intermittent doses. A continuous infusion may be started at 1.0-1.5 mcg/kg/hour.

Switching Dosing Strategies

A patient may be switched from an intermittent dosing schedule to a continuous IV infusion if they experience persistent or recurrent hypoglycemia despite repeated boluses. A continuous infusion provides more stable plasma concentrations of octreotide. Conversely, a patient on an infusion may be transitioned to intermittent SC injections as their condition stabilizes before discontinuing therapy.

Managing Recurrent Hypoglycemia

In this acute care setting, a “missed dose” corresponds to a failure to prevent recurrent hypoglycemia. If a patient on an intermittent schedule becomes hypoglycemic before the next dose is due, a supplemental bolus may be administered, and the clinician should consider shortening the dosing interval or switching to a continuous infusion. Blood glucose must be monitored closely throughout therapy.

Safety Alerts

While generally well-tolerated for short-term use, be aware of the following:

• Common Side Effects: Nausea, vomiting, abdominal pain, and injection site pain.
• Monitoring: Blood glucose should be monitored frequently (e.g., hourly at first, then every 2-4 hours once stable). Monitor electrolytes as needed.
• Cautions: Use with caution in patients with significant renal or hepatic impairment, as octreotide clearance may be reduced.

Frequently Asked Questions (FAQ)

1. Why is octreotide used for sulfonylurea overdose?

Sulfonylureas cause the pancreas to release excess insulin. Octreotide inhibits this insulin release, addressing the root cause of the hypoglycemia, whereas dextrose only treats the symptom.

2. Does the calculator provide doses for neonates?

The calculator is intended for pediatric and adult populations. Neonatal dosing can be complex and requires specialist consultation.

3. What is the maximum recommended bolus dose for a child?

The calculator caps the weight-based bolus and intermittent dose at 50 mcg, which is a commonly cited maximum for pediatric patients in this setting.

4. Can this calculator be used for hypoglycemia from other causes?

No. This tool is specifically designed for sulfonylurea-induced hypoglycemia. Its use for other causes (e.g., insulin overdose) is not indicated and may not be effective.

5. What is the typical duration of therapy?

Duration depends on the specific sulfonylurea ingested (due to varying half-lives) and the patient’s clinical response. Therapy is typically continued for 24-48 hours and weaned off once the patient is normoglycemic off dextrose.

6. Does the calculator adjust for renal or hepatic impairment?

No, the tool provides standard dosing recommendations. Lower doses or extended intervals may be required in patients with severe renal or hepatic dysfunction, requiring clinical judgment.

7. What are the output units?

All doses are provided in micrograms (mcg) for bolus/intermittent options and micrograms per hour (mcg/hour) for continuous infusions.

8. How should the IV infusion be prepared?

Refer to your institution’s pharmacy guidelines. Octreotide is typically diluted in a compatible solution like 0.9% sodium chloride or 5% dextrose in water.

References

• Howland MA. Antidotes in depth (A30): Octreotide. In: Nelson LS, Howland MA, Lewin NA, et al, eds. Goldfrank’s Toxicologic Emergencies. 11th ed. McGraw Hill; 2019.
• Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76(3):752-756. doi:10.1210/jcem.76.3.8445033
• Dougherty PP, Klein-Schwartz W. Octreotide’s role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol. 2010;6(2):199-206. doi:10.1007/s13181-010-0062-8
• FASENRA (benralizumab) Prescribing Information. U.S. Food and Drug Administration. FDA Drugs@FDA Database. (Note: This is a general link; specific labels can be searched for).